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cals and diagnostic (or staging) tests, more than offset by cost savings related to
lower consumption of other health care resources.
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OBJECTIVES: A systematic review of the literature was performed to gather all
official recommendations on the prevention in infants of allergic manifestations
(AM), and, more specifically, atopic dermatitis (AD), by using hydrolyzed infant
formulas (HF) such as partially or extensively hydrolyzed formula (PHF; EHF).
METHODS:OVID MEDLINE® and the grey literature were searched by two reviewers
using the keywords AM, AD, prevention and guidelines. A third person acted as
adjudicator in case of disagreement. Of interest were recommendations pertaining
to the prevention of AM issued by national or regional associations of medical
professionals. RESULTS: This review yielded 11 sets of guidelines published for
Australia, France, Germany, Spain, Switzerland (all n1), Europe and the US (both
n3) between 1999 and 2010. Most guidelines included AD either specifically (n3)
or in the broad context of AMs. Six guidelines (of which 2 recommended PHF over
EHF) endorsed the use of HFs for the prevention of AM in “at risk” infants when
exclusive breastfeeding was not or no longer possible. Two other publications did
not explicitly recommend HFs, but rather formulas with a documented reduced
allergenicity. The need for an appropriate level of nutritional support was stressed
in one publication. Five guidelines acknowledged that not all HFs have the same
protective benefit. . Four publications underlined the importance of sound clinical
evidence when determining the preventive efficacy of HFs. None of the guidelines
based their recommendations on recent evidence from meta-analyses focusing on
a specific brand of PHF NAN-HA®. CONCLUSIONS: HFs and specifically PHFs are
endorsed for the prevention of AMs. The need for a strong validity and universality
of the clinical evidence and methodology is acknowledged by national or regional
medical associations. Hence, recent evidence regarding the preventive efficacy of a
specific brand of PHF, NAN-HA®, should provide the basis for new recommenda-
tions.
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OBJECTIVES: Patch testing is a well-established method to determine whether
contact sensitization to certain agents has occurred and it can directly influence
the clinical outcome of patients with allergic contact dermatitis (ACD) where de-
tection of causative allergens is crucial for appropriate prevention and treatment.
Its positive predictive value, however, is influenced by many variables. In particu-
lar, not all patients referred for patch testing actually have ACD and not all positive
reactions are clinically relevant. The objective of our study was to develop an
outcome indicator of patch testing. METHODS: We identified and measured as a
possible indicator the ratio of patients with allergic and/or photo-allergic contact
dermatitis clinically cured/improved as a result of identification of relevant aller-
gens. Patients with positive reactions considered relevant to their current derma-
titis were interviewed by telephone 2 months after patch/photo-patch testing in
order to assess their clinical outcome in relation to the recommended elimination
of supposedly relevant allergens. We parallely evaluated the prevalence of referral
diagnosis different from ACD in patients whose test results were
negative/non-relevant.RESULTS:Over a 4-year period positive reactions were seen
in 1397 out of 2857 tested patients. Relevance was considered current in 578 sub-
jects, and 506 of them were interviewed. Remission/significant improvement fol-
lowing allergen(s) contact avoidance was reported by 431 patients, the outcome
indicator (431/506) thus scoring 85.2%. Among the 75 patients who reported no
improvement, 41 had not avoided contact with the offending substance(s), 17 had
other persistent concomitant skin conditions, and 17 were unchanged despite
elimination of the alleged relevant allergens. The likely diagnoses of patients
whose test results were negative/non-relevant were: non-eczematous diseases
(39% of total patients), endogenous eczema (22%), irritant contact dermatitis (10%),
unknown (5%), possible ACD from unidentified haptens (4%). CONCLUSIONS: The
ratio of relevantly patch-test-positive patients resolved/improved after allergen
avoidance is a useful patch-testing outcome indicator.
PRS75
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OBJECTIVES: A particular challenge for economic evaluation of new pharmaceuti-
cals is to address the potential for conflict between 1) the available evidence that
informs decisions about reimbursement coverage, and 2) the reality of how prod-
ucts are used in clinical practice. The aim of this study is to explore the issue of
divergence between actual and evaluated drug pathways and resultant conse-
quences for the appropriateness of technology appraisals and reimbursement cov-
erage decisions. METHODS: We develop a generic decision analytic model to illus-
trate the issue of divergence between actual and evaluated drug pathways arising
from a new product changing the number of lines of therapy available to patients,
rather than displacing existing therapies. Under this generic model, incremental
costs and effects are potentially affected by response to therapy and the clinical
decision to maintain or switch treatment. The potential effects on the estimated
cost-effectiveness of new drugs from the misspecification of the drug pathway are
illustrated using COPD as a case study disease area and prescription utilisation
data from Australia. RESULTS: In the case of treatments for COPD, cost-effective-
ness of new therapies is overestimated when displacement is assumed, but the
real-world utilisation of new products involves additions to reimbursement sched-
ules without displacement and when effect size decreases with therapy line. We
define this as pathway misspecification bias and consider that it may arise in all
disease areas and drug classes. We demonstrate that the size of the bias is posi-
tively related to the proportion of non-responders. CONCLUSIONS: We demon-
strate that without provision to withdraw funding from existing lines of therapy,
cost-effectiveness analysis to inform reimbursement decision-making should be
expanded to include further routine modelling of the likely use of products in
clinical practice. We demonstrate that providing for the withdrawal of funding for
existing technologies may provide for more efficient funding decisions.
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OBJECTIVES: To identify evidence gaps for future economic modelling of Chronic
Obstructive Pulmonary Disease (COPD) by reviewing published Conceptual Models
and studies reporting associations between end-points and disease outcomes.
METHODS: A systematic literature search was undertaken to identify English lan-
guage publications since 2000 in Medline and Embase describing Conceptual Mod-
els of COPD and studies reporting associations between end-points and disease
outcomes. Studies were reviewed against inclusion/exclusion criteria and those
including therapeutic interventions were excluded at screening. RESULTS: Forty-
one published papers were identified: 7 conceptual models of COPD and 34 articles
on associations between endpoints and disease outcomes. Of the 7 conceptual
models, 6 described single aspects of COPD (cognitive function, dyspnoea, brain
function, design of patient related interventions, activity and functional perfor-
mance). Only 1 described a broader set of determinants of health status in COPD
patients (physiological functioning, patient complaints, functional impairment
and quality of life.) 2 review papers on cognitive function and functional perfor-
mance and 1 reporting determinants of functional performance and dyspnoea
based on patient/expert interviews were identified. 31 studies using regression
analyses to estimate associations between relevant parameters in COPD, including
symptoms (mainly dyspnoea), health status, exercise, lung function, exacerba-
tions, quality of life, biomarkers, co-morbidities, mortality and healthcare utiliza-
tion were found. No studies on the use of conceptual models for economic model-
ling in COPD were identified. None of the studies presented a comprehensive set of
determinants of disease progression and outcomes. CONCLUSIONS: It is recom-
mended that models used to support economic evaluations of health care inter-
ventions are based on conceptual models capturing all relevant aspects of the
disease and outcomes of value. The available evidence does not provide a full
spectrum of relationships between diagnosis, disease progression and outcomes
needed for a comprehensive disease based economic model in COPD.
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OBJECTIVES: Applying innovative methods to clinical trial data to identify and
characterize unobserved subgroups of differential responders. METHODS: Data
from three COPD clinical trials was retrospectively analysed using Growth Mixture
Models (GMMs): INHANCE (indacaterol 150g and 300g vs tiotropium 18g and
placebo); INLIGHT-2 (indacaterol 150g vs salmeterol 50g and placebo); and IN-
VOLVE (indacaterol 300g and 600g vs formoterol 12g and placebo). GMMs were
conducted on SGRQ Symptoms Domain data at baseline, 12 weeks, and six months
to identify unobserved subgroups. Baseline characteristics were compared be-
tween emergent subgroups of differential responders in post hoc analyses.
RESULTS:Within INHANCE and INLIGHT-2, two subgroups of patients emerged per
treatment arm: responders (improvement) and non-responders (little change/de-
terioration). Within INOLVE, three subgroups of patients emerged per treatment
arm: responders, non-responders, and partial-responders. When responders were
analysed separately, mean treatment effects in terms of SGRQ Symptom scores
were generally larger than when all patients were included: INHANCE responder
improvements ranged from 8 -12 units compared with 7-14 for all patients;
INLIGHT-2 responder improvements were 3 -13 units versus 3 -8 for all patients;
INVOLVE responder improvements were 5 -17 units vs 3 -11 for all patients. Within
each trial, responders made up the largest proportion of the sample (55% - 82%) but
non-/partial-responder groups were large enough and different enough to dampen
treatment effects when group means were analyzed as a whole. Responders had
significantly better baseline SGRQ Symptom scores than non-responders. Further
significant differences were found between non-responders, partial-responders
and responders in terms of smoking history, age, and breathlessness.
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CONCLUSIONS: GMMs have the potential to increase understanding of treatment
effects and identify patients more likely to benefit from treatment. The ability of
baseline characteristics to predict responders/non-responders needs to be tested
prospectively.
Sensory Systems Disorders – Clinical Outcomes Studies
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OBJECTIVES: To investigate the associations between ocular discomfort, compli-
ance and efficacy of IOP lowering drugs. METHODS: This was a prospective obser-
vational survey. Centres were selected at random from the CEGEDIM list. Consec-
utive patients treated with an IOP lowering fixed combination drug (prostaglandin
analogues excluded) were included. IOP was collected at two visits (delay fixed by
the investigator). Self-reported compliance measured by validated questionnaires
(EDSQ, TSQM and TEO) and self-reported ocular discomfort (13 items with a focus
at instillation and during the day) based on a questionnaire developed according to
international patient reported outcome recommendations were collected at the
last visit. Patients were classified into 3 groups of compliance (good, minor and
major issues) using the TEO published algorithm. Comparisons between compli-
ance groups were made by ANOVA and chi-square tests. Adjustments were made
for confounding variable unbalances. RESULTS: 410 patients (66 years old, 237
females, 101 ocular hypertensions) were included. 32.9% reported good compli-
ance, 55.9% minor and 11.2% major compliance issues. Patients reporting either red
eyes (P0.02), stinging (P0.007), feeling of sand in the eyes (P0.0009), dry eye
(P0.02), or blurry vision (P0.002) were more likely to report compliance issues.
Patients in the good compliance group reported 3.2 ocular discomfort concerns, 4.5
in the minor and 5.2 in the major compliance issue group (P0.0002). The proba-
bilities to report no concern were 24.2%, 12.7% and 11.9% (P0.02), respectively. An
association between IOP control and compliance was reported in the group of
patients that did not have a change in treatment at the first visit: patients in the
good compliance group had an IOP decrease of 0.9 mmHg, 0.3 mmHg in the minor
and a 0.2 mmHg increase in the major compliance issue group. CONCLUSIONS:
Ocular discomfort issues reported by patients might impact compliance leading to
poor IOP control.
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OBJECTIVES: To determine the prevalence, demographics and treatment charac-
teristics of patients with visual impairment (VI) due to diabetic macular edema
(DME) in a real-world Canadian setting. METHODS: Records from a longitudinal
population-based database of more than 170,000 patients in 53 family practice
clinics in southwestern Ontario, Canada were analyzed between January 1, 2008 to
December 31, 2009. Patient records were limited to those aged 18 years of age and
older. These records contained chart-abstracted information such as visit diagno-
sis, medications and consultation notes. Initial extractions of control, diabetic and
DME patients with VI, defined as best corrected visual acuity20/40 in the DME eye,
were accomplished utilizing International Classification of Disease codes (ICD9/
ICD10); reviewing patient charts for text entries of symptoms that supported a
diagnosis of diabetes and DME and concomitant comorbidity; and reviewing pa-
tient treatment records unique to DME with VI including consultation notes and
hospital discharge summaries. Demographic characteristics, comorbidities, and
treatment were reported. RESULTS: 8368 patients with type 1 or 2 diabetes and a
control cohort of 76,077 patients were extracted for this analysis. Among diabetic
patients, prevalence of DME was 15.7%. Average duration of diabetes among pa-
tients with DME was 19 years. More patients with DME had hypertension (66%), or
vascular disease (28%) than the control cohort (p0.05). The prevalence of VI due to
DME was 2.56%. Mean age was 6417. In patients with VI due to DME, 53% had focal
and 47% had diffuse edema. For both focal and diffuse edema, the most common
treatment was laser monotherapy, used in 62% and 53% of cases, respectively.
CONCLUSIONS: : In a real-world setting, among patients with diabetes, we ob-
served the prevalence of VI due to DME at 2.56% . Laser monotherapy was the most
common treatment.
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OBJECTIVES: Retinal vein occlusion (RVO) has an abrupt onset and is an important
cause of visual morbidity. Macular edema (ME) is the most common cause of visual
impairment (VI) in patients with RVO. The Canadian incidence of VI due to ME
secondary to RVO is unknown. This study aimed to determine the annual incidence
and characteristics of patients with ME secondary to branch RVO (BRVO) and cen-
tral RVO (CRVO) in a real-world Canadian setting. METHODS: Records from a lon-
gitudinal population-based database of more than 170,000 patients in 53 family
practice clinics in southwestern Ontario, Canada were analyzed between January 1,
2008 and December 31, 2009. These records contained chart-abstracted informa-
tion such as visit diagnosis, medications and consultation notes. Initial extractions
of control cohort and RVO patients with ME and VI (defined as best corrected visual
acuity 20/40 in the RVO eye), were accomplished utilizing International Classifi-
cation of Disease codes (ICD9/ICD10); reviewing patient charts for text entries of
symptoms that supported a diagnosis of RVO and concomitant comorbidity; and
reviewing patient treatment records unique to RVO including consultation notes
and hospital discharge summaries. Demographic characteristics and comorbidi-
ties were reported. RESULTS: Seventy-three (53 with BRVO and 20 with CRVO) of
47,166 patients over 40 years (mean age 6117 years) with new diagnosis of RVO
and a control cohort of 76,077 patients were extracted for this analysis. The annual
incidence of VI due to ME secondary to BRVO and CRVO was 0.056% and 0.021%,
respectively. More RVO patients had hypertension (68 vs. 18%) or dyslipidemia (16
vs. 10%) than control cohort (p0.05). One-quarter of RVO patients had a history of
vascular disease, primarily MI and stroke. CONCLUSIONS: In a real-world setting,
the annual incidence of VI due to ME secondary to BRVO and CRVO was 0.056% and
0.021%, respectively. RVO is associated with several vascular comorbidities.
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OBJECTIVES: The presence of the preservative benzalkonium chloride (BAK) at
0.01% concentration in commercialized prostaglandin eye drops for glaucoma is
known to increase the risk of ocular surface disease (OSD), which worsens with the
extent of exposure to BAK. We aimed to estimate longer term clinical outcomes
with travoprost preserved with Polyquad® 0.001% instead of BAK. METHODS: A
Markov microsimulation model was developed (TreeAge) to assess the develop-
ment of OSD and disease progression (Mean Defect [MD], in db) over 10 years, in
patients initiating travoprost with Polyquad® followed by travoprost/beta-blocker
fixed combination vs. the same sequence using BAK-preserved drops. Initial pa-
tient’s characteristics came from distributions on age (normal), sex, OSD presence,
disease stage (uniform) and anticipated progression rates (triangular). The risk of
developing OSD in aging population was derived from a US incidence study, mul-
tiplied by independent risk factors (age, sex, duration and amount of BAK-contain-
ing drops received). Rates of disease progression (db/year) came from landmark
studies in OHT/glaucoma, multiplied by independent accelerating factors (disease
stage, treatment line, OSD severity, non-compliance). Compliance was expected by
experts to be 20% (absolute) better with Polyquad® vs. BAK-preserved drops.
RESULTS: Using 3000 trials (mean age 57 years, 57% female, 14% with initial OSD,
mean MD -4db), 47.6% [41.5-53.6%] of patients receiving in first and second line
BAK-preserved travoprost treatments are expected to have OSD at 10 years versus
31.7% [28.5-35.1%] with Polyquad®. In OHT/early glaucoma patients, the model
predicted the progression to advanced glaucoma (MD-12db) of 13.2% [12.0-14.4%]
with Polyquad® versus 18.1% [16.7-19.5%] with BAK. In patients diagnosed with
moderate glaucoma, 1.9% [1.4-2.4%] versus 5.6% [4.8-6.4%] progressed to blindness
(MD-24db) respectively. CONCLUSIONS: The model estimated that OSD inci-
dence was reduced by 33% and glaucoma disease progression was significantly less
frequent after 10 years of use of Polyquad® versus BAK-containing travoprost eye
drops.
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OBJECTIVES: The progression of glaucoma is measured by a Mean Defect (MD) of
the perimetry in decibels (db), from an early disease stage (6db loss), until mod-
erate (6-12db loss), advanced stages (12-24db loss) and eventually blindness (24db
loss). The rate of disease progression is highly variable between individuals and
hard to predict. The objective of this study was to analyze the change in MD of
glaucoma patients in a real-life setting in Germany. METHODS: We analyzed pa-
tient-level data from a German observational study in ocular hypertension (OHT)
and glaucoma, with retrospective collection of MD measures (db). Descriptive sta-
tistics were derived on the rate of disease progression (db loss/year, obtained by
dividing the change in MD by the duration of observation). The change in MD in
best eye between the time of first treatment until last MD measure was included in
a generalized linear regression, adjusting for age, sex, presence of cataract, time
since first treatment, initial MD and initial glaucoma stage (OHT, early/moderate or
advanced). RESULTS: MD data was available for 57 patients (53% female, mean age
67 /12 years). The mean (SD) time from first treatment until last MD measure
was 7.0 (3.7) years. The mean (SD) MD was -4.5db (4.7) at first treatment and -6.0db
(6.8) at last assessment (i.e. average rate of progression of -0.21db/year, all stages).
In 12 OHT patients, 50% had no MD worsening, while 50% lost on average -0.26db/
year. Based on the adjusted analysis, the initial diagnosis was significantly associ-
ated with the amount of db loss over time (early/moderate glaucoma -0.19db/year
/0.13, advanced -0.66db/year /0.22, p0.038). CONCLUSIONS: The rates of
disease progression measured over more than 7 years in glaucoma patients was
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